True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Phase 2 study findings demonstrate the clinical efficacy of pevonedistat plus azacitidine for the treatment of higher-risk MDS and low-blast AML.
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.
What is the mechanism of action of sabatolimab therapy in patients with intermediate- to high-risk MDS and/or AML?
Pevonedistat plus azacitidine yields comparable safety to azacitidine monotherapy and demonstrates improvements in OS, EFS, and response rates in patients with higher-risk MDS.
True or false: Guadecitabine maintenance therapy after allogeneic stem cell transplantation has yielded promising survival rates and manageable safety in high-risk patients with MDS/AML.
Guadecitabine, when given as maintenance therapy following allo-SCT, showed promising relapse-free survival rates with manageable safety in high-risk MDS/AML patients.
Study findings support further exploration of specific dosing regimens of sabatolimab in patients with intermediate- to very high-risk MDS/AML.
The FDA has approved an oral combination of decitabine and cedazuridine for the treatment of adults with MDS.